Physician profile
Kyle Hamann
NPI 1992213458
$1,409.62
in general payments reported to CMS, 2019-2025
17 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $389 · 2024: $367 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $314.23 | 2023-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $241.54 | 2024-2025 | Eohilia, Gattex, Entyvio |
| Ardelyx, INC. | $131.65 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.91 | 2023 | Trulance |
| Novo Nordisk INC | $100.54 | 2023-2025 | Wegovy |
| Abbvie INC. | $94.99 | 2023 | |
| Qol Medical, LLC | $91.58 | 2025 | Sucraid |
| Gilead Sciences, INC. | $75.97 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.74 | 2023-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $33.99 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $32.37 | 2023 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $26.65 | 2024 | Rexulti |
| Mallinckrodt Hospital Products INC. | $23.39 | 2025 | Acthar |
| Paratek Pharmaceuticals, INC. | $20.03 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $16.22 | 2023 | Xarelto |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.05 | 2023 | Farxiga |
| Exact Sciences Corporation | $13.77 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Hamann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.